Esperion Therapeutics | ESPR - Operating Expenses

Stock Price
2.74
Daily Change
-0.11 -3.86%
Monthly
-16.21%
Yearly
82.67%
Q1 Forecast
2.69

Esperion Therapeutics reported $83.21M in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
AbbVie USD 10.81B 13.45B Dec/2025
Alnylam Pharmaceuticals USD 965.32M 84.27M Dec/2025
Alterity Therapeutics Limited AUD 7.78M 3M Jun/2023
Amarin USD 51.48M 113K Dec/2025
Amgen USD 5.9B 773M Dec/2025
Biogen USD 1.88B 81.4M Sep/2025
BioMarin Pharmaceutical USD 676.18M 131.65M Dec/2025
Cipla INR 60.98B 1.06B Dec/2025
CSL USD 5.7B 2.82B Dec/2025
Cytokinetics USD 196.12M 27.43M Dec/2025
Daiichi Sankyo JPY 468.57B 15.34B Dec/2025
Eli Lilly USD 10.31B 1.09B Dec/2025
Esperion Therapeutics USD 83.21M 14.06M Dec/2025
Geron USD 58.8M 2.31M Dec/2025
Grifols EUR 1.99B 217.4M Dec/2025
Halozyme Therapeutics USD 211.07M 74.73M Dec/2025
Heron Therapeutics USD 40.55M 1.46M Dec/2025
Ionis Pharmaceuticals USD 418M 101.1M Dec/2025
Merck USD 10.16B 558M Dec/2025
Minerva Neurosciences USD 4.52M 155.46K Dec/2024
Moderna USD 1.54B 259M Dec/2025
Nektar Therapeutics USD 85.09M 109.3M Sep/2025
Pfizer USD 12.91B 79.89B Dec/2025
PTC Therapeutics USD 246.3M 38.78M Dec/2025
Puma Biotechnology USD 49.26M 3.2M Jun/2024
Regeneron Pharmaceuticals USD 2.99B 27.97B Dec/2025
Sanofi EUR 10.51B 1.21B Dec/2025
Sarepta Therapeutics USD 853.02M 390.78M Dec/2025
United Therapeutics USD 804.8M 5.79B Dec/2025
Vanda Pharmaceuticals USD 466M 20.33M Sep/2025